Generics BRIC (Brazil, Russia, India, China) Industry Guide 2013-2022

  • ID: 4663786
  • Report
  • Region: BRIC, Brazil, China, India, Russia
  • 113 pages
  • MarketLine
1 of 3
Generics BRIC (Brazil, Russia, India, China) Industry Guide 2013-2022

Summary

The BRIC Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2013-17, and forecast to 2022). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Questions Answered:
  • What was the size of the BRIC generics market by value in 2017?
  • What will be the size of the BRIC generics market in 2022?
  • What factors are affecting the strength of competition in the BRIC generics market?
  • How has the market performed over the last five years?
  • How large is the BRIC generics market in relation to its regional counterparts?
Scope
  • Essential resource for top-line data and analysis covering the BRIC generics market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.
  • Brazil, Russian Federation, India and China (BRIC) are the emerging and fast growing countries within the generics industry and had a total market value of $90,535.3 million in 2017. Russia was the fastest growing country with a CAGR of 12.5% over the 2013-17 period.
  • Within the generics industry, China is the leading country among the BRIC nations with market revenues of $61,399.8 million in 2017. This was followed by India, Russia and Brazil with a value of $14,395.1, $8,304.7, and $6,435.8 million, respectively.
  • China is expected to lead the generics industry in the BRIC nations with a value of $86,778.1 million in 2022, followed by India, Russia, Brazil with expected values of $20,551.5, $12,412.3 and $9,201.9 million, respectively.
Reasons to buy
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the BRIC generics market
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the BRIC generics market
  • Leading company profiles reveal details of key generics market players’ BRIC operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the BRIC generics market with five year forecasts by both value and volume
  • Compares data from Brazil, Russia, India, and China, alongside individual chapters on each country
READ MORE
Note: Product cover images may vary from those shown
2 of 3
Introduction
What is this report about?
Who is the target reader?
How to use this report
Definitions
BRIC Generics
Industry Outlook
Generics in Brazil
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in China
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in India
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Russia
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Company Profiles
Leading Companies
Appendix
Methodology
About the Author

List of Tables
Table 1: BRIC generics industry, revenue($m), 2013-22
Table 2: BRIC generics industry, revenue($m), 2013-17
Table 3: BRIC generics industry, revenue($m), 2017-22
Table 4: Brazil generics market value: $ million, 2013-17
Table 5: Brazil generics market volume: % of total pharma, 2013-17
Table 6: Brazil generics market geography segmentation: $ million, 2017
Table 7: Brazil generics market value forecast: $ million, 2017-22
Table 8: Brazil generics market volume forecast: % of total pharma, 2017-22
Table 9: Brazil size of population (million), 2013-17
Table 10: Brazil gdp (constant 2005 prices, $ billion), 2013-17
Table 11: Brazil gdp (current prices, $ billion), 2013-17
Table 12: Brazil inflation, 2013-17
Table 13: Brazil consumer price index (absolute), 2013-17
Table 14: Brazil exchange rate, 2013-17
Table 15: China generics market value: $ billion, 2013-17
Table 16: China generics market volume: % of total pharma, 2013-17
Table 17: China generics market geography segmentation: $ billion, 2017
Table 18: China generics market value forecast: $ billion, 2017-22
Table 19: China generics market volume forecast: % of total pharma, 2017-22
Table 20: China size of population (million), 2013-17
Table 21: China gdp (constant 2005 prices, $ billion), 2013-17
Table 22: China gdp (current prices, $ billion), 2013-17
Table 23: China inflation, 2013-17
Table 24: China consumer price index (absolute), 2013-17
Table 25: China exchange rate, 2013-17
Table 26: India generics market value: $ million, 2013-17
Table 27: India generics market volume: % of total pharma, 2013-17
Table 28: India generics market geography segmentation: $ million, 2017
Table 29: India generics market value forecast: $ million, 2017-22
Table 30: India generics market volume forecast: % of total pharma, 2017-22
Table 31: India size of population (million), 2013-17
Table 32: India gdp (constant 2005 prices, $ billion), 2013-17
Table 33: India gdp (current prices, $ billion), 2013-17
Table 34: India inflation, 2013-17
Table 35: India consumer price index (absolute), 2013-17
Table 36: India exchange rate, 2013-17
Table 37: Russia generics market value: $ million, 2013-17
Table 38: Russia generics market volume: % of total pharma, 2013-17
Table 39: Russia generics market geography segmentation: $ million, 2017
Table 40: Russia generics market value forecast: $ million, 2017-22
Table 41: Russia generics market volume forecast: % of total pharma, 2017-22
Table 42: Russia size of population (million), 2013-17
Table 43: Russia gdp (constant 2005 prices, $ billion), 2013-17
Table 44: Russia gdp (current prices, $ billion), 2013-17
Table 45: Russia inflation, 2013-17
Table 46: Russia consumer price index (absolute), 2013-17
Table 47: Russia exchange rate, 2013-17
Table 48: Ache Laboratorios Farmaceuticos SA: key facts
Table 49: EMS SA: key facts
Table 50: Eurofarma Laboratorios SA: key facts
Table 51: Sanofi SA: key facts
Table 52: Sanofi SA: key financials ($)
Table 53: Sanofi SA: key financials (€)
Table 54: Sanofi SA: key financial ratios
Table 55: China Grand Pharmaceutical and Healthcare Holdings Limited: key facts
Table 56: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials ($)
Table 57: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials (CNY)
Table 58: China Grand Pharmaceutical and Healthcare Holdings Limited: key financial ratios
Table 59: Mylan N.V.: key facts
Table 60: Mylan N.V.: key financials ($)
Table 61: Mylan N.V.: key financial ratios
Table 62: Novartis AG: key facts
Table 63: Novartis AG: key financials ($)
Table 64: Novartis AG: key financial ratios
Table 65: Aurobindo Pharma Limited: key facts
Table 66: Aurobindo Pharma Limited: key financials ($)
Table 67: Aurobindo Pharma Limited: key financials (Rs.)
Table 68: Aurobindo Pharma Limited: key financial ratios
Table 69: Cipla Limited: key facts
Table 70: Cipla Limited: key financials ($)
Table 71: Cipla Limited: key financials (Rs.)
Table 72: Cipla Limited: key financial ratios
Table 73: Lupin Ltd: key facts
Table 74: Lupin Ltd: key financials ($)
Table 75: Lupin Ltd: key financials (Rs.)
Table 76: Lupin Ltd: key financial ratios
Table 77: Sun Pharmaceutical Industries Ltd: key facts
Table 78: Sun Pharmaceutical Industries Ltd: key financials ($)
Table 79: Sun Pharmaceutical Industries Ltd: key financials (Rs.)
Table 80: Sun Pharmaceutical Industries Ltd: key financial ratios
Table 81: Abbott Laboratories: key facts
Table 82: Abbott Laboratories: key financials ($)
Table 83: Abbott Laboratories: key financial ratios
Table 84: Krka, d. d., Novo mesto: key facts
Table 85: Krka, d. d., Novo mesto: key financials ($)
Table 86: Krka, d. d., Novo mesto: key financials (€)
Table 87: Krka, d. d., Novo mesto: key financial ratios
Table 88: Teva Pharmaceutical Industries Limited: key facts
Table 89: Teva Pharmaceutical Industries Limited: key financials ($)
Table 90: Teva Pharmaceutical Industries Limited: key financial ratios

List of Figures
Figure 1: BRIC generics industry, revenue($m), 2013-22
Figure 2: BRIC generics industry, revenue($m), 2013-17
Figure 3: BRIC generics industry, revenue($m), 2017-22
Figure 4: Brazil generics market value: $ million, 2013-17
Figure 5: Brazil generics market volume: % of total pharma, 2013-17
Figure 6: Brazil generics market geography segmentation: % share, by value, 2017
Figure 7: Brazil generics market value forecast: $ million, 2017-22
Figure 8: Brazil generics market volume forecast: % of total pharma, 2017-22
Figure 9: Forces driving competition in the generics market in Brazil, 2017
Figure 10: Drivers of buyer power in the generics market in Brazil, 2017
Figure 11: Drivers of supplier power in the generics market in Brazil, 2017
Figure 12: Factors influencing the likelihood of new entrants in the generics market in Brazil, 2017
Figure 13: Factors influencing the threat of substitutes in the generics market in Brazil, 2017
Figure 14: Drivers of degree of rivalry in the generics market in Brazil, 2017
Figure 15: China generics market value: $ billion, 2013-17
Figure 16: China generics market volume: % of total pharma, 2013-17
Figure 17: China generics market geography segmentation: % share, by value, 2017
Figure 18: China generics market value forecast: $ billion, 2017-22
Figure 19: China generics market volume forecast: % of total pharma, 2017-22
Figure 20: Forces driving competition in the generics market in China, 2017
Figure 21: Drivers of buyer power in the generics market in China, 2017
Figure 22: Drivers of supplier power in the generics market in China, 2017
Figure 23: Factors influencing the likelihood of new entrants in the generics market in China, 2017
Figure 24: Factors influencing the threat of substitutes in the generics market in China, 2017
Figure 25: Drivers of degree of rivalry in the generics market in China, 2017
Figure 26: India generics market value: $ million, 2013-17
Figure 27: India generics market volume: % of total pharma, 2013-17
Figure 28: India generics market geography segmentation: % share, by value, 2017
Figure 29: India generics market value forecast: $ million, 2017-22
Figure 30: India generics market volume forecast: % of total pharma, 2017-22
Figure 31: Forces driving competition in the generics market in India, 2017
Figure 32: Drivers of buyer power in the generics market in India, 2017
Figure 33: Drivers of supplier power in the generics market in India, 2017
Figure 34: Factors influencing the likelihood of new entrants in the generics market in India, 2017
Figure 35: Factors influencing the threat of substitutes in the generics market in India, 2017
Figure 36: Drivers of degree of rivalry in the generics market in India, 2017
Figure 37: Russia generics market value: $ million, 2013-17
Figure 38: Russia generics market volume: % of total pharma, 2013-17
Figure 39: Russia generics market geography segmentation: % share, by value, 2017
Figure 40: Russia generics market value forecast: $ million, 2017-22
Figure 41: Russia generics market volume forecast: % of total pharma, 2017-22
Figure 42: Forces driving competition in the generics market in Russia, 2017
Figure 43: Drivers of buyer power in the generics market in Russia, 2017
Figure 44: Drivers of supplier power in the generics market in Russia, 2017
Figure 45: Factors influencing the likelihood of new entrants in the generics market in Russia, 2017
Figure 46: Factors influencing the threat of substitutes in the generics market in Russia, 2017
Figure 47: Drivers of degree of rivalry in the generics market in Russia, 2017
Figure 48: Sanofi SA: revenues & profitability
Figure 49: Sanofi SA: assets & liabilities
Figure 50: China Grand Pharmaceutical and Healthcare Holdings Limited: revenues & profitability
Figure 51: China Grand Pharmaceutical and Healthcare Holdings Limited: assets & liabilities
Figure 52: Mylan N.V.: revenues & profitability
Figure 53: Mylan N.V.: assets & liabilities
Figure 54: Novartis AG: revenues & profitability
Figure 55: Novartis AG: assets & liabilities
Figure 56: Aurobindo Pharma Limited: revenues & profitability
Figure 57: Aurobindo Pharma Limited: assets & liabilities
Figure 58: Cipla Limited: revenues & profitability
Figure 59: Cipla Limited: assets & liabilities
Figure 60: Lupin Ltd: revenues & profitability
Figure 61: Lupin Ltd: assets & liabilities
Figure 62: Sun Pharmaceutical Industries Ltd: revenues & profitability
Figure 63: Sun Pharmaceutical Industries Ltd: assets & liabilities
Figure 64: Abbott Laboratories: revenues & profitability
Figure 65: Abbott Laboratories: assets & liabilities
Figure 66: Krka, d. d., Novo mesto: revenues & profitability
Figure 67: Krka, d. d., Novo mesto: assets & liabilities
Figure 68: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 69: Teva Pharmaceutical Industries Limited: assets & liabilities
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll